Details for Patent: 11,992,480
✉ Email this page to a colleague
Which drugs does patent 11,992,480 protect, and when does it expire?
Patent 11,992,480 protects ZORYVE and is included in two NDAs.
This patent has thirty-six patent family members in twelve countries.
Drugs Protected by US Patent 11,992,480
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arcutis | ZORYVE | roflumilast | CREAM;TOPICAL | 215985-002 | Jul 9, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS | ⤷ Sign Up | ||||
| Arcutis | ZORYVE | roflumilast | CREAM;TOPICAL | 215985-001 | Jul 29, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE AND OLDER | ⤷ Sign Up | ||||
| Arcutis | ZORYVE | roflumilast | FOAM;TOPICAL | 217242-001 | Dec 15, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN PATIENTS 9 YEARS OF AGE AND OLDER | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,992,480
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018282098 | ⤷ Sign Up | |||
| Australia | 2021214399 | ⤷ Sign Up | |||
| Brazil | 112019025748 | ⤷ Sign Up | |||
| Brazil | 112022015104 | ⤷ Sign Up | |||
| Canada | 3006836 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
